|
Briefing
|
- Drug Discovery AI – U.K. startup BenevolentAI uses artificial intelligence to predict which molecules or compounds can more effectively target diseases
- First Clinical Trial – To be held in 2018 in U.S. and Europe, targeting excessive daytime sleepiness in Parkinson’s disease
- Potential Therapies – Company currently researching cures for nervous system disease Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s, with 20 drugs being developed
- $115 Million in Funding – Received $115 million in funding on April 2018, which puts company’s valuation at $2 billion
|
|
Accelerator
|
|
|
Business Model and Practices
Business Model
and Practices
|
|
|
Sector
|
Healthcare/Health Sciences
|
|
Organization
|
BenevolentAI
|
|
Source
|
-
"BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development,"
-
Medeiros, J., "This AI unicorn is disrupting the pharma industry in a big way",
-
Lunden, I., "BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation",
-
Ramsey, L., "A startup that uses artificial intelligence to discover new drugs just landed a $2 billion valuation",
-
AcceleratingBiz analysis
|
|
Original Publication Date
|
April 19, 2018
|
